KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 11/05/24
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 MillionBusiness Wire • 11/04/24
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare TrustBusiness Wire • 11/04/24
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and ImmunologyBusiness Wire • 10/28/24
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)Business Wire • 10/18/24
KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema ForumBusiness Wire • 10/04/24
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary AngioedemaBusiness Wire • 09/30/24
KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)Business Wire • 09/26/24
KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare ConferenceBusiness Wire • 09/10/24
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024Business Wire • 09/06/24
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational UpdateBusiness Wire • 09/05/24
KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary AngioedemaBusiness Wire • 09/03/24
KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin SymposiumBusiness Wire • 08/29/24
KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary AngioedemaBusiness Wire • 08/15/24
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial ResultsBusiness Wire • 07/11/24
KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11Business Wire • 06/27/24
Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 LaunchSeeking Alpha • 06/24/24
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary AngioedemaBusiness Wire • 06/18/24
KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024Business Wire • 06/06/24
KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024Business Wire • 06/03/24
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary AngioedemaBusiness Wire • 05/31/24
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024Business Wire • 05/24/24